<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537366</url>
  </required_header>
  <id_info>
    <org_study_id>EssaiClinique-VENDETTA</org_study_id>
    <nct_id>NCT02537366</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for Non-invasive Ventilation After Chest Trauma</brief_title>
  <acronym>VENDETTA</acronym>
  <official_title>Dexmedetomidine for Non-invasive Ventilation After Chest Trauma (VENDETTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crossover randomized controlled double blinded trial :

        -  The primary endpoint is the duration of Non Invasive Ventilation (NIV) session (minutes)
           with dexmedetomidine (DEX) or placebo.

        -  Secondary endpoints will be the sedation level as assessed by the Richmond Agitation
           Sedation Scale (RASS), the number of interventions to allow the completion of NIV
           session, the pain intensity level as assessed by visual analogue scale, the morphine and
           ketamine consumption during NIV sessions, the comparison of blood gas measurements
           before and after NIV sessions, the reproducibility of NIV cycles. The side effects of
           DEX will be notified.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of NIV session</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>Minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Richmond Agitation-Sedation Scale</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>From -5 (Unarousable) to +4 (Combative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of interventions on NIV settings</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>Morphine administration during NIV session (mg/kg/h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketamine consumption</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>Ketamine administration during NIV session (mg/kg/h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain visual analogue scale</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>From 0 (no pain) to 10 (worst pain possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of arterial partial pressure of Carbon dioxide (CO2) before and after NIV session</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of arterial partial pressure of dioxygen (O2) before and after NIV session</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of potential hydrogen (pH) before and after NIV session</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproductibility of NIV sessions</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradycardia</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>Mean arterial pressure less than 55 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>During ICU stay (expected average of 2 weeks)</time_frame>
    <description>Heart rate less than 40 / mn</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Thoracic Injuries</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.07 ml/kg/h Adaptation to sedation status by changing infusion speed of 0.02 ml/kg/h every 30 minutes up to 0.14 ml/kg/h Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine diluted to 10 µg/ml in Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.7 µg/kg/h (= 0.07 ml/kg/h) Adaptation to sedation status by changing infusion speed of 0.2 µg/kg/h (= 0.02 ml/kg/h) every 30 minutes up to 1.4 µg/kg/h (= 0.14 ml/kg/h) Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>DEX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blunt chest trauma with thoracic trauma score&gt; 6, ICU admission and spontaneous
             breathing

        Exclusion Criteria:

          -  Contra indication for NIV or Dexmedetomidine as specified by the French marketing
             authorization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thibaut TROUVE-BUISSON, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thoracic Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

